コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 cids from the C-terminus of the 11 beta-HSD2 enzyme protein.
2 phyllide reductase mRNA and immunodetectable enzyme protein.
3 olysis and resulting in irreversible loss of enzyme protein.
4 time-dependent conformational change in the enzyme protein.
5 mogenates reflects the steady state level of enzyme protein.
6 -hour incorporation of [3H]-leucine into the enzyme protein.
7 ic conformational constraints imposed on the enzyme protein.
8 after incorporation of [3H]-leucine into the enzyme protein.
9 t these drugs did not affect the mass of the enzyme protein.
10 e further extended to the detection of other enzyme proteins.
11 GSAT, or by the cellular abundance of these enzyme proteins.
12 ignificant increases in mitochondrial marker enzyme proteins.
13 umber of reaction types using at least eight enzymes/proteins.
14 code antioxidant and Phase II detoxification enzymes/proteins.
15 orated into newly synthesized zinc-requiring enzymes/proteins.
17 ect of urocortin to a decrease in a specific enzyme protein and a subsequent decrease in the concentr
18 generally modest, when the patterns for the enzyme protein and mRNA levels for GST pi were correlate
19 octapeptide and reduced pancreatic digestive enzyme protein and mRNA levels, thus suggesting mild pan
21 pEG on plasmids may result in an increase of enzyme protein and overproduction of this essential amin
24 cates that this property is intrinsic to the enzyme protein, and cannot be attributed to the lipid en
28 sily eluted in a buffer, indicating that the enzyme proteins are probably secreted from, and deposite
30 and specific inhibitor of the cell-essential enzyme Protein Arginine Methyltransferase-5 (PRMT5).
32 tem and for insoluble, high molecular weight enzyme-protein assemblies in biopsy derived myofibrils.
33 Cells transduced with NO synthase expressed enzyme protein at consistently high levels for several p
34 hed clinical testing, including gene-editing enzymes, protein-based inhibitors, and RNA-based therape
35 ires LexA repressor, and the RecA and RecBCD enzymes--proteins best known for their role as initiator
38 ic activity of the corresponding recombinant enzyme protein carrying the mutation p.Lys53Arg expresse
40 cing the unproductive hydrolytic cleavage of enzyme-protein covalent intermediates that form during t
41 tween genetic mutations, endogenous residual enzyme proteins (cross-reactive immunologic material), d
46 rsional motions of multiple hydrogens of the enzyme protein during the conformational change that acc
47 ional genomics to identify a missing pathway enzyme, protein engineering to enable the functional exp
48 s reflected by down-regulation of urea cycle enzyme protein expression and accumulation of its metabo
52 k for potential off-target inhibition of the enzyme protein farnesyltransferase (PFTase) by commercia
53 s have exploited the high specificity of the enzyme protein farnesyltransferase (PFTase) to site-spec
55 lation is carried out by a pair of cytosolic enzymes, protein farnesyltransferase (FTase) and protein
56 as the recognition motif for two prenylation enzymes, protein farnesyltransferase (FTase) and protein
58 nd selectivity toward FTase over the related enzyme, protein geranylgeranyltransferase type I (GGTase
61 to assess the in vivo turnover rate of AAAD enzyme protein in the rhesus macaque striatum by monitor
64 e) storage rates and fatty acid (FA) storage enzymes/proteins in omental and abdominal subcutaneous f
67 at wild-type levels, indicating that another enzyme protein is responsible for the physiologically re
68 lead to selective inhibitors of the related enzyme protein kinase A (PKA), and several specific modi
73 nsgenic flies specifically inhibited for the enzyme protein kinase C dissociate the acquisition of le
74 -7 that expresses a transgene coding for the enzyme protein kinase C-alpha (PKC-alpha), is both malig
77 lly dependent on the cytosolic dsRNA-binding enzyme protein kinase R and does not require signalling
79 and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site d
80 hat control the activation of DNA processing enzymes, protein kinases, and scaffold proteins to coord
81 cellular proteins, including lipid modifying enzymes, protein kinases, GTPases, and proteins involved
83 ast Tup1p repressor is one of only a few non-enzyme proteins known to interact directly with the amin
88 p in cells is limited by a ubiquitous repair enzyme, protein l-isoaspartyl methyltransferase (PIMT).
89 -l-methionine and the commercially available enzyme, protein l-isoaspartyl-O-methyltransferase, and (
90 ental temporal changes in enzyme activities, enzyme protein level, and steady-state transcript abunda
91 by a radioisotope incorporation method) and enzyme protein mass (determined by Western blotting and
92 ic and inhibition studies with the OXA-24/40 enzyme, protein mass spectrometry analysis and docking s
93 ase-1 (but similar amounts of ADMA-producing enzyme, protein methyltransferase-1) in the human failin
94 ase, a disorder that is caused by loss of an enzyme (protein O-mannose beta-1,2-N-acetylglucosaminylt
95 iated by the endoplasmic reticulum-localized enzyme protein-O-fucosyltransferase 2 (POFUT2) was descr
96 as mendelian traits involving structural or enzyme proteins of the respiratory chain, mitochondrial
97 tive and/or positive feedback, bi-functional enzymes, protein oligomerization and discrete or continu
99 evels of PSY and several other carotenogenic enzyme proteins overaccumulate in the clpc1, clpp4, and
100 bly and is governed by the concentrations of enzyme, protein, peptide, the structure of the peptide,
102 an inhibitor screen for one such target, the enzyme protein phosphatase methylesterase-1 (PME-1), whi
103 gamma (B'gamma) subunit of an essential host enzyme, protein phosphatase 2 A (PP2A), is repurposed as
104 structures of both calcineurin and a related enzyme, protein phosphatase-1, revealed that this class
107 terial activity was obtained at a DH of 30% (enzyme/protein ratio 0.04 U/mg of protein, enzyme activi
108 d upon to validate the potential of numerous enzymes/proteins/receptors as therapeutic targets in GBM
109 of nuclear genes encoding heme biosynthetic enzymes, proteins required for mitochondrial genome tran
110 and tertiary structural modifications of PPO enzyme-protein revealed MW's lethality primarily due to
111 mage bioluminescence from Renilla luciferase enzyme/protein (RL) by injecting the substrate coelenter
112 dynamics of hydration at the surface of the enzyme protein Subtilisin Carlsberg, whose single Trp re
113 rect correlation between enzyme activity and enzyme protein, suggesting that the dynamic time course
115 s types of cancers, including nearly 400 non-enzyme proteins that are challenging to target by tradit
116 oforms within the same subclass of signaling enzyme, proteins that have a high degree of structural s
118 enetic deletion of the insulin-desensitizing enzyme protein tyrosine phosphatase (PTP)1B in db/db mic
120 project to discover novel inhibitors for the enzyme protein tyrosine phosphatase-1B (PTP1B), a tyrosi
123 ts of PEPC mRNA, PEPC specific activity, and enzyme protein were greater in proteoid roots than in no
125 activity often occurs without a reduction in enzyme protein, which negates the use of immunocytochemi
126 NQO1) is a xenobiotic metabolizing cytosolic enzyme/protein with important functional properties towa